Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Femasys Inc. Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives April 18, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update March 28, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape March 21, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility March 20, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 March 13, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution March 06, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF February 28, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer February 06, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women January 26, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology January 23, 2024 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine December 15, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer November 30, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch November 28, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech November 15, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY PMCB Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update November 14, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. EU MDR Final Audit Successfully Completed October 26, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons October 25, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Regains Compliance with Nasdaq Listing Requirements October 11, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine October 04, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. MDSAP Surveillance Audit Successfully Completed October 03, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate September 27, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution September 25, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control September 20, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Obtains Medical Device Establishment License from Health Canada August 31, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update August 10, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc August 03, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women June 26, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences June 15, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023 June 14, 2023 From Femasys Inc. Via GlobeNewswire Tickers FEMY Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.